Dennis Dong Hwan Kim
YOU?
Author Swipe
View article: New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients
New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Open
Tyrosine kinase inhibitors (TKIs) significantly improved outcomes for patients with chronic myeloid leukemia (CML), enabling optimal treatment responses and near-normal life expectancy. Despite optimal responses, clonal evolution (CE) in P…
View article: Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival
Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival Open
View article: Endothelial activation and stress index ( <scp>EASIX</scp> ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment
Endothelial activation and stress index ( <span>EASIX</span> ) as a biomarker to predict ruxolitinib failure for steroid‐refractory acute graft‐versus‐host disease treatment Open
Summary Steroid‐refractory acute graft‐versus‐host disease (SR‐aGvHD) remains a significant challenge after haematopoietic cell transplantation (HCT). While ruxolitinib (RUX) has shown efficacy for SR‐aGvHD, failure predictors are poorly d…
View article: Olverembatinib in chronic myeloid leukemia: is less actually better?
Olverembatinib in chronic myeloid leukemia: is less actually better? Open
Not available.
View article: Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based <scp>GVHD</scp> Prophylaxis
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based <span>GVHD</span> Prophylaxis Open
Introduction Myeloablative conditioning (MAC) for acute myeloid leukemia (AML) improves disease control by reducing relapse risk but is associated with higher non‐relapse mortality (NRM). Reduced‐intensity conditioning (RIC) aims to minimi…
View article: Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL Open
The efficacy of and disease control afforded by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia in chronic phase (CML-CP) have led to increased longevity and thus the continued pursuit of alternative therapies that are effica…
View article: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms Open
Myelodysplastic/myeloproliferative overlap neoplasms (MDS/MPN) are rare hematological malignancies. We analyzed the outcomes of 75 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for MDS/MPN. Graft‐versus‐host…
View article: Central Nervous System Manifestations of Graft‐Versus‐Host Disease
Central Nervous System Manifestations of Graft‐Versus‐Host Disease Open
View article: Blood-based Epigenetic Instability Linked to Human Aging and Disease
Blood-based Epigenetic Instability Linked to Human Aging and Disease Open
The abundance, dynamics, and context-dependent heterogeneity of DNA methylation - where a pattern considered abnormal in one cell type may be normal in another - poses challenges in identifying methylation abnormalities linked to disease r…
View article: Exploring Outcomes by Ethnicity in Allogeneic Hematopoietic Cell Transplantation
Exploring Outcomes by Ethnicity in Allogeneic Hematopoietic Cell Transplantation Open
Background: Clinical outcome disparities among racial and ethnic groups have been described following allogeneic hematopoietic cell transplantation (HCT). This study investigated the impact of race and ethnicity on HCT outcomes in a multi-…
View article: Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study
Asciminib versus bosutinib following 2 or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study Open
What is this summary about? This is a summary of a publication about the ASCEMBL study, which was published in Blood in November of 2021. Overall, researchers wanted to learn how well asciminib works compared to bosutinib, and how safe it …
View article: PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation
PTCy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation Open
Posttransplant cyclophosphamide (PTCy) is a promising graft-versus-host disease (GVHD) prophylaxis in haploidentical and matched unrelated donor hematopoietic stem cell transplantation (HSCT), but its role in matched sibling donor (MSD) tr…
View article: Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation
Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation Open
Pure red cell aplasia (PRCA) is a rare but significant complication following major ABO‐incompatible allogeneic hematopoietic stem cell transplantation (HSCT). The persistence of recipient B lymphocytes producing anti‐donor isohemagglutini…
View article: Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with <i>BCR</i>::<i>ABL1</i> digital <scp>PCR</scp> in chronic myeloid leukemia patients
Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with <i>BCR</i>::<i>ABL1</i> digital <span>PCR</span> in chronic myeloid leukemia patients Open
Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of mol…
View article: Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia Open
This study aimed to validate the 2022 European LeukemiaNet (ELN) risk stratification for acute myeloid leukemia (AML). A total of 624 newly diagnosed AML patients from 1998 to 2014 were included in the analysis. Genetic profiling was condu…
View article: Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development
Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development Open
This is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challen…
View article: Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes Open
Advancements in genomics are transforming the clinical management of chronic myeloid leukemia (CML) toward precision medicine. The impact of somatic mutations on treatment outcomes is still under debate. We studied the association of somat…
View article: Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine Open
In conclusion, the revised ELN-2022 risk stratification model may have improved the risk classification of elderly AML patients treated with hypomethylating agents compared to the ELN-2017 risk stratification model.
View article: Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing
Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing Open
The first treatment given to cGVHD patients was corticosteroids. Ruxolitinib was the most used second-line treatment. About 40% of cGVHD patients received >2 treatments, and scleroderma was associated with more LOT. There is a need for mor…
View article: Dual T Cell Depletion for Graft versus Host Disease Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies
Dual T Cell Depletion for Graft versus Host Disease Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults with Hematological Malignancies Open
The ideal immunosuppressive agents to complement post-transplant cyclophosphamide (PTCy) in PBSC-based haploidentical hematopoietic cell transplantation (haplo-HCT)remain debated. This study looks at our experience with ATG-PTCy-Cyclospori…
View article: Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data
Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data Open
Background Cytomegalovirus (CMV) is associated with morbidity and mortality following allogeneic hematopoietic cell transplantation (alloHCT). Letermovir is a novel antiviral agent that prevents CMV reactivation in alloHCT patients, with l…
View article: European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Open
View article: Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD
Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD Open
Graft-versus host disease (GVHD) is one of the major limitations to allogeneic hematopoietic stem cell transplantation (HCT). Although corticosteroids with calcineurin inhibitors are established first line-therapy for chronic graft-versus-…
View article: A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes
A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes Open
Background: Chronic graft-versus-host disease (cGVHD) is a common cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Tyrosine kinase inhibitors (TKIs), including ruxolitinib, imatinib, and ibruti…
View article: Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia
Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia Open
Introduction Inherited DDX41 mutations cause familial predisposition to hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with the majority of DDX41 mutated MDS/AMLs described to date harb…
View article: The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine Open
Background/Aims: We evaluated the role of next-generation sequencing (NGS)-based disease monitoring for elderly patients diagnosed with acute myeloid leukemia (AML) who received decitabine therapy.Methods: A total of 123 patients aged > 65…
View article: Tyrosine kinase inhibitors for the frontline management of CML: an overview
Tyrosine kinase inhibitors for the frontline management of CML: an overview Open
The introduction of Tyrosine Kinase Inhibitors (TKI) for the treatment of chronic myeloid leukemia (CML) has revolutionized CML therapy. These agents have increased the life expectancy of CML patients to 98% of those in the general populat…
View article: Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up
Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up Open
Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HSCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples…
View article: Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL Open
Asciminib, the first BCR::ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (CM…
View article: Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia
Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia Open
Purpose We evaluated the characteristics of CCAAT/enhancer-binding protein α (CEBPA) mutations and the significance of a basic leucine zipper in-frame mutation (bZIPin-f) of CEBPA in patients with acute myeloid leu…